Tuesday 30 April 2024
Internal Reference Number: FOI_6857
Date Request Received: 08/11/2022 00:00:00
Date Request Replied To: 13/12/2022 00:00:00
This response was sent via: By Email
Request Summary: Breast cancer treatments
Request Category: Private Individuals
| Question Number 1: In the past 3 months, how many Breast Cancer patients (at any stage) were treated with: - Abemaciclib monotherapy - Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole) - Tamoxifen monotherapy - Abemaciclib + Tamoxifen | |
| Answer To Question 1: We are unable to provide data on the numbers of patients receiving aromatase inhibitor monotherapy or tamoxifen monotherapy The number of patients receiving abemaciclib in combination with other agents- <5 Abemaciclib monotherapy - 0 Abemaciclib + Tamoxifen - 0 | |
| Question Number 2: In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with: - Abemaciclib + Aromatase inhibitor (e.g. anastrazole, exemestane, letrozole) - Taxane and/or Anthracycline (monotherapy or in combination) - Any other active systemic anti cancer therapy | |
| Answer To Question 2: - Abemaciclib + Aromatase inhibitor (e.g. anastrazole, exemestane, letrozole) <5 - Taxane and/or Anthracycline (monotherapy or in combination) 27 - Any other active systemic anti cancer therapy 22 | |
| Question Number 3: How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti cancer therapies: - Anthracycline (e.g. doxorubicin or epirubicin) as a single agent - Atezolizumab +Nab-paclitaxel/Paclitaxel - Pembrolizumab - Sacituzumab Govitecan - Parp Inhibitors (Olaparib/Talazoparib) - Eribulin as a single agent or in combination - Capecitabine as a single agent - Platinum (e.g. carboplatin or cisplatin) as a single agent - Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - Taxane and/or Anthracycline in combination - Any other active systemic anti-cancer therapy | |
| Answer To Question 3: - Anthracycline (e.g. doxorubicin or epirubicin) as a single agent 0 - Atezolizumab +Nab-paclitaxel/Paclitaxel <5 - Pembrolizumab 0 - Sacituzumab Govitecan 0 - Parp Inhibitors (Olaparib/Talazoparib) <5 - Eribulin as a single agent or in combination 0 - Capecitabine as a single agent 6 - Platinum (e.g. carboplatin or cisplatin) as a single agent 0 - Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 0 - Taxane and/or Anthracycline in combination <5 - Any other active systemic anti-cancer therapy <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
